Indaptus Therapeutics (INDP) Profit After Tax (2020 - 2026)

Indaptus Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 43.94% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$18.9 million (down 19.75% YoY), while the FY2025 annual figure was -$20.8 million, down 38.79% from the prior year.
• Profit After Tax for Q1 2026 stood at -$2.5 million, up from -$8.1 million in the prior quarter.
• The five-year high for Profit After Tax was -$2.5 million in Q1 2026, with the low at -$8.1 million in Q4 2025.
• The 5-year median for Profit After Tax is -$3.8 million (2022), against an average of -$4.0 million.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax slumped 644.07% in 2022, then soared 43.94% in 2026.
• Indaptus Therapeutics' Profit After Tax stood at -$3.6 million in 2022, then retreated by 11.98% to -$4.0 million in 2023, then fell by 3.2% to -$4.1 million in 2024, then plunged by 96.38% to -$8.1 million in 2025, then surged by 68.68% to -$2.5 million in 2026.
• Business Quant data shows INDP's Profit After Tax at -$2.5 million in Q1 2026, -$8.1 million in Q4 2025, and -$3.0 million in Q3 2025.